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The global rise in the prevalence of obesity and associated co-morbidities such as type 2 diabetes,
cardiovascular disease, and cancer represents a major public health concern. The biological
response to increased consumption of palatable foods or a reduction in energy expenditure is highly
variable between individuals. A more detailed mechanistic understanding of the molecular, physio-
logical, and behavioral pathways involved in the development of obesity in susceptible individuals is
critical for identifying effective mechanism-based preventative and therapeutic interventions.Introduction
Obesity is defined as an increase in fat mass that is sufficient to
adversely affect health (Sperrin et al., 2014; Whitlock et al.,
2009). While the absolute quantification of fat mass is usually
only performed in the research setting, body mass index (BMI;
weight in kg/height in meters2) is a useful surrogate marker. Us-
ing the World Health Organization (WHO) definition of a BMI
more than 30 kg/m2 to define obesity, 30% of Americans and
10%–20% of Europeans are classified as obese, with the preva-
lence rising in many developing countries (http://www.who.int).
As body mass index increases, so does the relative risk of type
2 diabetes, hypertension, and cardiovascular disease (Berring-
ton de Gonzalez et al., 2010). Furthermore, an increase in the
prevalence of childhood obesity (11%–17% in Europe and the
US) has driven an increase in medical problems such as type 2
diabetes mellitus in adolescents (Fagot-Campagna, 2000). At a
societal level, obesity is associated with disability, mortality,
and substantial health costs. At an individual level, severe
obesity is often associated with a multitude of clinical problems,
including sleep disturbance and respiratory difficulties, joint and
mobility issues, as well as considerable social stigma, which can
affect quality of life as well as educational attainment and job
opportunities (Puhl and Brownell, 2001).
In this Review, we provide a perspective on the contribution of
environmental, genetic, and other factors to the development of
obesity. We discuss how these factors impact the molecular and
physiological mechanisms that regulate energy intake and en-
ergy expenditure in humans and highlight ongoing strategies to
dissect the complex neural circuits and pathways that modulate
energy homeostasis and their potential to be targeted by preven-
tative and therapeutic interventions.
Obesity as a Disorder of Energy Homeostasis
Humans, like other mammals, are able to regulate their body
weight over long periods of time despite day-to-day variation
in the number of calories consumed and in levels of energy
expenditure, irrespective of the level of adiposity. Fundamen-
tally, factors that influence changes in body weight must
ultimately disrupt the balance between energy intake and expen-
diture over time, the utilization of substrates (fat, protein, carbo-hydrate), and/or nutrient partitioning (storage of excess calories).
Physiological studies in healthy normal weight individuals have
shown that total energy expenditure decreases by an average
of 10% with acute caloric restriction and increases with caloric
excess (Ravussin et al., 2014). However, in humans, the homeo-
static regulation of energy balance is easily overwhelmed by
external stimuli. For example, in a study in which people were
given free access to food, the average daily intake exceeded
150% of energy requirements. In such experimental settings,
and potentially in the free-living environment, some individuals
seem more readily able to resist weight change with overeating,
possibly due to inter-individual variation in the energy costs of
weight gain (Ravussin et al., 2014).
Environmental Factors Drive the Rise in Obesity
Prevalence
The increasing prevalence of obesity worldwide (an approximate
doubling in the last 30 years), the inverse relationship between
obesity and socioeconomic class, and the secular trend toward
increasing obesity in developing countries associated with
urbanization provide clear evidence of the environmental influ-
ences on weight gain (Ogden et al., 2014; Popkin, 2006). The
adoption of relatively sedentary lifestyles due to reduced
physical activity at work and in leisure time coupled with an
abundance of easily available, energy-rich, highly palatable
foods represents a nutrition transition that, according to the
World Health Organization, is now one of the greatest risk
factors for ill health worldwide (http://www.hsph.harvard.edu)
(Figure 1). Interestingly, some recent analyses of trends in
obesity prevalence have suggested a decline or stabilization of
obesity prevalence, especially in children in the US and some
European countries, findings that are consistent with dynamic
models using prevalence data and birth and death rates (Ogden
et al., 2014; Thomas et al., 2014). However, many countries have
either increasing (China) or decreasing (European countries)
birth rates, so the potential global impact of these estimations
is not readily predictable. Recent studies show that second-
generation migrants to the US from all ethnic groups are heavier
than their parents who migrated but that people from some
ethnic groups are more likely to gain weight than others uponCell 161, March 26, 2015 ª2015 Elsevier Inc. 119
Figure 1. Contribution of Genes and Environmental Factors to
Weight Gain
Human adiposity is influenced by complex interactions between genetic and
environmental influences. The current environment potently facilitates the
development of obesity. Abundance of highly processed food has a major
impact on energy intake, whereas numerous other environmental factors, such
as television watching, leisure activities, and transport, negatively affect
energy expenditure. In any environment, there is a variation in body fat andBMI
in large part influenced by genetic variation disrupting energy homeostasis by
either decreasing energy expenditure or increasing energy intake.transitioning to a more obesogenic environment (Singh and
Lin, 2013), suggesting that, in addition to strong environmental
drivers, genetic factors play a role in influencing obesity
susceptibility.
Individual Susceptibility to Weight Gain Is Highly
Variable—Role of Genetic Factors
In any environment, whether energy rich or energy lacking, there
is considerable individual variation in body weight and fat mass,
suggesting that human adiposity is influenced by complex
interactions between genetic, developmental, behavioral, and
environmental influences. Evidence for genetic contributions
to body weight comes from family, twin, and adoption studies,
which cumulatively demonstrate that the heritability (fraction
of the total phenotypic variance of a quantitative trait attribut-
able to genes in a specified environment) of BMI is between
0.71 and 0.86 (Silventoinen et al., 2008). Heritability estimates
can change over time and can differ between populations.
Recent studies in a UK sample of 5,092 twin pairs aged 8–11
years growing up during a time of dramatic rises in obesity
confirmed substantial heritability for BMI and waist circumfer-
ence (77% for both), while there was a very modest shared-
environment effect, and the remaining environmental variance
was unshared (Wardle et al., 2008b). Interestingly, similar herita-
bility estimates have been found when studying monozygotic
and dizygotic twins who were reared together and apart (Allison
et al., 1996) and in adoption studies in which adopted children
were discovered to have body sizes that were more similar to
those of their biological parents than their adopted parents
(Sørensen et al., 1989).120 Cell 161, March 26, 2015 ª2015 Elsevier Inc.The high heritability of phenotypes related to obesity supports
the contribution of genetic factors but does not indicate the num-
ber of genes or how those genes interact with environmental
factors. The ‘‘thrifty gene hypothesis’’ suggests that we harbor
genetic variants that favor efficient food collection and fat depo-
sition to survive periods of famine and that, in the face of the easy
availability of food, these genes/variants are disadvantageous.
However, an alternative hypothesis is that obesity is selected
against by the risk of predation. This hypothesis suggests that
random mutations and genetic drift, rather than directed selec-
tion, have influenced changes in the population distribution of
fat mass that may be more readily reconcilable with the findings
that, even in Western societies, most people are not obese
(Speakman, 2007).
Evidence for the interaction of inherited factors with changes
in energy intake and expenditure was provided by landmark
experimental overfeeding studies by Bouchard and colleagues,
who showed that weight gain induced by overfeeding mono-
and dizygous twin pairs under direct supervision was highly
correlated within twin pairs but varied widely among pairs of
twins (Bouchard et al., 1990). Similarly, the response to negative
energy balance via an exercise regime was also heritable (Bou-
chard et al., 1996). Notably, the inter-twin correlations were
greater for weight loss than for weight gain, suggesting tighter
biological control of the response to negative energy balance.
Hypothalamic Circuits Regulating Energy Homeostasis
Ultimately, signals from cumulative genetic and environmental
influences that reflect changing energy status have to be de-
tected and integrated by brain circuits that can, through their
projections, regulate energy balance. In the early 1900s, clinical
reports of patients with tumors involving hypothalamo-pituitary
structures associated with food-seeking behavior and obesity
suggested that the hypothalamus may be involved in the regu-
lation of body weight. Chemical and electrolytic lesioning ex-
periments in animals in the 1930s and 1940s established the
key role of the hypothalamus in the regulation of energy homeo-
stasis. The degree of weight gain/weight loss seen in these ex-
periments was, in part, determined by the size and precise
location of the lesions, which suggested that there were spe-
cific hypothalamic circuits that promote or suppress feeding
behavior (Anand and Brobeck, 1951; Hetherington and Ranson,
1940).
The hypothalamus is essentially a hub for key circuits that
integrate sensory inputs; compare those inputs to basic ‘‘set
points,’’ or parameters for body temperature, electrolyte
balance, sleep-wake cycle, circadian rhythms, and energy ho-
meostasis; and then initiate a set of responses by activating
autonomic, endocrine, and behavioral outputs that aim to main-
tain these set points (homeostasis). The hypothalamus regulates
autonomic nervous system activation via neurons that directly
innervate parasympathetic and sympathetic preganglionic neu-
rons, as well as neurons in the brainstem that control autonomic
reflexes. Individual pre-autonomic neurons project to multiple
levels of the spinal cord, where they selectively innervate end
organs such as the heart, kidney, and adipose tissue. Autonomic
innervation of the pancreas contributes to the regulation of insu-
lin and glucagon secretion.
Figure 2. Leptin: A Master Regulator of Hu-
man Energy Homeostasis
The adipocyte-derived hormone leptin signals
nutritional depletion and initiates a series of
changes in energy intake, energy expenditure,
autonomic nervous system tone, and neuroendo-
crine function in order to maintain energy homeo-
stasis. The hypothalamus primarily coordinates
many of these processes and also regulates
circadian rhythms, temperature, and sleep.
Through neuronal connections to the amygdala
and periaquaductal gray (PAG) the hypothalamus
also modulates a range of behaviors and moods
such as stress, anger, anxiety, and aggression. Via
its connections to the brainstem—direct and indi-
rect via the cortex—neurons in the hypothalamus
modulate autonomic nervous system tone which,
in turn, influences many metabolic processes in
peripheral tissues, such as the liver, pancreas,
heart, and gut. Beyond energy homeostasis, leptin
also has important effects on immune function and
puberty.Molecular Characterization of the Circuits Involved in
Energy Homeostasis
While the location of the neural circuits regulating energy homeo-
stasis was apparent from the early 1930s, a critical advance
came as a result of parabiosis experiments in inbred strains of
mice with severe obesity (ob/ob and db/db), which suggested
the existence of a circulating factor that regulated weight (Cole-
man, 1973; Coleman and Hummel, 1969). The identification of
this hormone, leptin, through positional cloning of the ob gene
that was mutated in severely obese ob/ob mice (Zhang et al.,
1994) paved the way for the identification and characterization
of the neural circuits regulating energy homeostasis. Normaliza-
tion of the phenotype of severely obese leptin-deficient ob/
ob mice (characterized by increased food intake, reduced
energy expenditure, hypogonadism, low thyroid hormone levels,
elevated levels of corticosterone, and low blood pressure), by
central leptin administration proved that leptin is a key regulator
of energy homeostasis (Campfield et al., 1995; Halaas et al.,
1995; Pelleymounter et al., 1995).
Leptin—A Master Regulator of Human Energy
Homeostasis
Early human studies showing that leptin mRNA concentrations in
adipose tissue and serum leptin concentrations correlated posi-
tively and very closely with the amount of fat mass (Considine
et al., 1996; Maffei et al., 1995) led to the notion that leptin’s
primary role was to signal increasing energy stores. However,
it rapidly became clear that most people are relatively resistant
to rising endogenous or exogenously administered leptin
(Heymsfield et al., 1999). Instead, leptin’s physiological role in
humans, as in mice (Ahima et al., 1996), appears to be to signal
nutritional depletion, such that fasting or weight loss results in aCell 16fall in leptin levels (Chan et al., 2003),
which then triggers a series of changes
in energy intake, energy expenditure,
and neuroendocrine function in order to
maintain energy homeostasis.Evidence supporting leptin’s role in human physiology
emerged from the identification and characterization of severely
obese people with homozygous loss-of-function mutations that
reduce the production, secretion, or biological activity of leptin
(Montague et al., 1997; Strobel et al., 1998; Wabitsch et al.,
2015) or disrupt signaling through the leptin receptor (Cle´ment
et al., 1998; Farooqi et al., 2007b). While these disorders are
rare, being found in 1%–5% of patients with severe obesity, their
characterization has demonstrated that leptin regulates energy
balance, neuroendocrine pathways, and the autonomic nervous
system (Figure 2). These genetic findings have been supported
and extended by elegant studies bymany investigators in normal
weight in the context of fasting or the weight-reduced state
(Rosenbaum et al., 2002, 2005; Welt et al., 2004) and in patients
with lipodystrophic syndromes characterized by relative leptin
deficiency due to a loss of adipose tissuemass (Oral et al., 2002).
Impaired leptin signaling in humans is characterized by an
intense drive to eat (hyperphagia), reduced sympathetic tone,
mild hypothyroidism, hypogonadism, and impaired T-cell-medi-
ated immunity, features that are reversed with the administration
of recombinant human leptin in people with mutations in the lep-
tin gene (Farooqi et al., 1999, 2002; Licinio et al., 2004; Ozata
et al., 1999). Leptin also appears to be a major driver of the in-
crease in blood pressure seen with weight gain, as blood pres-
sure is low in obese mice and humans with disrupted leptin
signaling (in contrast to diet-induced obesity in rodents/more
common forms of obesity in humans) (Simonds et al., 2014).
Leptin mediates its effects by binding to the long form of the
leptin receptor expressed on hypothalamic neuronal populations
in the arcuate nucleus of the hypothalamus and other brain re-
gions (Mu¨nzberg and Myers, 2005). While homozygous muta-
tions that disrupt the expression, binding activity, and signaling1, March 26, 2015 ª2015 Elsevier Inc. 121
of the LEPR have been reported (Cle´ment et al., 1998; Farooqi
et al., 2007b), mutations that disrupt the downstream signaling
cascade have not as yet been clearly associated with obesity.
One possible exception is the adaptor molecule, Src homology
2 (SH2) B adaptor protein 1 (SH2B1), which is a key endogenous
positive regulator of leptin sensitivity (Maures et al., 2007).
However, SH2B1mutations have not been shown to disrupt lep-
tin sensitivity, and SH2B1 modulates signaling by a variety of
receptor tyrosine kinases, which may explain the additional phe-
notypes, including severe insulin resistance and behavioral ab-
normalities, reported in mutation carriers (Doche et al., 2012).
Leptin as a Therapeutic Agent
Recombinant human leptin (metreleptin) is highly effective in pa-
tients with no circulating or bioinactive leptin and in those with
low endogenous levels with exercise-induced amenorrhea and
lipodystrophy. Recombinant leptin has been administered suc-
cessfully to patients with congenital leptin deficiency for more
than 15 years on a named patient basis and was recently
approved by the Food and Drug Administration (FDA) for the
treatment of generalized lipodystrophy. In contrast, metreleptin
has minimal efficacy for more common forms of obesity, which
may represent a leptin-tolerant or leptin-resistant state (Heyms-
field et al., 1999). In a recent clinical trial, leptin administered in
combination with another weight loss agent, pramlintide, a syn-
thetic analog of the pancreatic peptide amylin, had beneficial
effects on weight loss, although the precise mechanisms under-
lying these effects are not entirely clear (Smith et al., 2007). A
number of intervention studies have shown that some of the
counter-regulatory responses to caloric restriction can be modi-
fied by leptin administration, including changes in skeletal mus-
cle and autonomic and neuroendocrine adaptation (Rosenbaum
et al., 2002, 2005). This form of intervention could be a useful
adjunct in weight-loss maintenance, an area that merits further
exploration.
Melanocortin Peptides and Their Receptors
Leptin stimulates primary neurons in the arcuate nucleus of the
hypothalamus, which express pro-opiomelanocortin (POMC),
which is posttranslationally processed to yield the melanocortin
peptides (alpha, beta, and gamma MSH), which are agonists
at melanocortin 3 and 4 receptors (Mc3r and Mc4r) expressed
on second-order neurons. Leptin signaling modulates energy
balance through a combination of melanocortin-dependent/
independent pathways. These hypothalamic pathways interact
with other brain centers to coordinate energy intake and energy
expenditure (Morton et al., 2014).
Several lines of evidence support the critical role of melano-
cortin signaling in human energy balance. Homozygous null
mutations in POMC result in severe obesity (Krude et al.,
1998), while heterozygous loss-of-function mutations in a- and
b-melanocyte-stimulating hormone (a- and b-MSH) significantly
increase obesity risk (Biebermann et al., 2006; Lee et al., 2006).
Targeted genetic disruption of Mc4r in mice leads to increased
food intake, increased lean mass, and linear growth (Huszar
et al., 1997), phenotypes that overlap entirely with those seen
in humans with loss-of-function mutations in MC4R (Farooqi
et al., 2003). Heterozygous MC4R mutations are found in 2%–122 Cell 161, March 26, 2015 ª2015 Elsevier Inc.5% of people with childhood-onset obesity, making this the
commonest gene in which highly penetrant variants contribute
to obesity (Farooqi et al., 2000; Vaisse et al., 2000). Most dis-
ease-causing MC4R mutations disrupt the expression and traf-
ficking of MC4R to the cell surface (Lubrano-Berthelier et al.,
2006; Xiang et al., 2006). In cells, pharmacological chaperones
can increase cell surface expression and signaling of mutant
GPCRs, which represents a potentially rational therapeutic
approach for this condition (Rene´ et al., 2010).
As complete loss-of-functionMC4Rmutations are associated
with a more severe form of obesity than partial loss-of-function
mutations (Farooqi et al., 2003), modulation of melanocortinergic
tone has been the focus of drug development strategies for
some time. However, despite promising pre-clinical studies,
the first generation of MC4R agonists were small molecules
that failed primarily due to safety issues (Van der Ploeg et al.,
2002), particularly increases in blood pressure. Loss-of-function
MC4R mutations are associated with a reduced prevalence
of hypertension, low systolic blood pressure, lower urinary
noradrenaline excretion, and reduced peripheral nerve sympa-
thetic nervous system activation, revealing that MC4R-express-
ing neurons represent a key circuit linking changes in weight with
changes in blood pressure (Greenfield et al., 2009; Sayk et al.,
2010). More recently, a potent melanocortin receptor agonist,
RM-493, has been administered as part of a Phase 1B proof-
of-concept clinical trial in obese patients, including one cohort
of patients with heterozygous loss-of-function mutations in
MC4R, in whom there was promising weight loss after 4 weeks.
If this compound moves forward, this may be one of the first ex-
amples of a personalized medicine approach for treating obesity
in people with a genetically characterized subtype of obesity.
Processing and Trafficking of Melanocortin Peptides
and Receptors
Melanocortin peptides are processed by enzymes including
prohormone convertase 1 (PCSK1), which is involved in the
cleavage of the precursor peptide POMC into ACTH, which is
then further cleaved to generate a-MSH by carboxypeptidase
E (Pritchard et al., 2002). Impaired POMC processing may
contribute to the obesity seen in people with homozygous/
compound heterozygous mutations in PCSK1 who also have
glucocorticoid deficiency, hypogonadotropic hypogonadism,
and postprandial hypoglycaemia (as a result of impaired pro-
cessing of proinsulin to insulin) (Jackson et al., 1997; O’Rahilly
et al., 1995). Impaired processing of gut-derived peptides may
contribute to the neonatal enteropathy seen in PCSK1 deficiency
(Jackson et al., 2003; Martı´n et al., 2013). Intriguingly, common
variants that affect the enzymatic activity of PCSK1 have
been associated with obesity in multiple European, Asian, and
Mexican populations, providing a clear example where both
common and rare variants in the same gene can influence a
spectrum of variation in body weight (Benzinou et al., 2008;
Choquet et al., 2013; Rouskas et al., 2012).
Several human obesity disorders (e.g., Alstro¨m syndrome and
Bardet-Beidl syndrome) disrupt genes involved in ciliary function
(Ansley et al., 2003). The role of neuronal cilia in protein traf-
ficking—in particular, of GPCRs involved in energy homeostasis
as well as in leptin signaling (Ainsworth, 2007)—is beginning to
Figure 3. Neural Circuits Involved in Eating
Behavior
Neural control of essential behaviors like eating
requires the integration of multiple neural signals
from different nodes in the brain. Dopaminergic
circuits in regions such as the striatum (2), ventral
tegmental area (5), and amygdala (7) encode
motivational salience and wanting. Opioidergic
circuits in regions such as the nucleus accumbens
and the ventral pallidum (4) encode hedonic liking.
These brain areas and others are integrated with
the hypothalamus, cortical areas, and brainstem
areas in the regulation of appetite and food
intake. Brain regions: (1) prefrontal cortex, (2)
dorsal striatum, (3) hippocampus, (4) nucleus ac-
cumbens/ventral pallidum, (5) ventral tegmental
area, (6) hypothalamus, (7) amygdala, (8) nucleus
of solitary tract, (9) gustatory/somatosensory
cortex.emerge. Furthermore, conditional postnatal knockout of proteins
involved in intraflagellar transport in neurons and specifically
when targeted to pomc neurons in mice results in hyperphagia
and obesity (Davenport et al., 2007).
Additionally, there is currently a great deal of interest in identi-
fying chaperones and accessory proteins that might modulate
melanocortin signaling and melanocortin-dependent pathways.
Mrap2, an accessory protein that interacts withMc4r (and poten-
tially other GPCRs) (Sebag et al., 2013) leads to obesity when
disrupted in mice (Asai et al., 2013). Rare variants in MRAP2
have been associated with severe obesity in humans, although
the detailed molecular mechanisms underlying this association
are not known (Asai et al., 2013).
Development and Maintenance of Neural Circuits
Involved in Eating Behavior
Functional dissection of the neuronal circuits involved in the
regulation of energy balance has until recently been limited
to dissecting relatively simple linear relationships between
neuronal populations that, in reality, are likely to be overlapping
and interconnected. Peripheral signals such as leptin can modu-
late the development and maintenance of these neural circuits
(Bouret et al., 2004) and their ability to adapt signaling by altering
synaptic inputs (Pinto et al., 2004).While our current understand-
ing of the dynamic and integrated nature of these neuronal
networks is still at an early stage, optogenetic tools and other
methodologies that permit the manipulation of gene expression
in specific populations of neurons are paving the way for major
advances in our understanding of the neural circuits connectingCell 16brain regions that contribute to the modu-
lation of eating behavior (Betley et al.,
2013; Wu et al., 2009) (Figure 3).
Several lines of evidence suggest
that brain-derived neurotrophic factor
(BDNF), a nerve growth factor that signals
via the tyrosine kinase receptor tropomy-
cin-related kinase B (TrkB), is important
not only in energy balance, but also
in anxiety and aggression. Haplo-insuffi-
cient mice and mice in which BDNF hasbeen deleted postnatally are obese with hyperphagia and hyper-
activity (Lyons et al., 1999; Xu et al., 2003); this unusual combi-
nation of phenotypes is also seen in individuals with genetic
disruption of BDNF and TrkB (Gray et al., 2006; Yeo et al.,
2004). While a Trkb agonist results in weight loss in mice (Tsao
et al., 2008), central administration had no effect on food intake
in primates (Perreault et al., 2013). Its potential utility in the treat-
ment of a number of neurodegenerative diseases is still being
explored (Yang et al., 2014).
Sim1 is a transcription factor involved in the development of
the paraventricular and supraoptic nuclei of the hypothalamus
and additionally may mediate signaling downstream of Mc4r
(Michaud et al., 1998). Sim1 haplo-insufficiency in mice and de-
letions, balanced translocations, and loss-of-function mutations
in humans cause severe obesity (Bonnefond et al., 2013; Holder
et al., 2000; Ramachandrappa et al., 2013). Oxytocin mRNA
levels are reduced in mouse models of Sim1 deficiency, and
oxytocin administration reduces food intake in Sim1-haploinsuf-
ficient animals (Kublaoui et al., 2008). Impaired oxytocinergic
signaling has also been implicated in the hyperphagia and
obesity seen in Prader-Willi Syndrome (PWS) (Swaab et al.,
1995), caused by lack of expression of a cluster of maternally im-
printed snoRNAs on chromosome 15 (Sahoo et al., 2008). Peo-
ple with PWS and with SIM1 mutations exhibit a spectrum of
behavioral abnormalities that overlap with autism-like features
and could be related to reduced oxytocinergic signaling (Rama-
chandrappa et al., 2013), although this has not been tested.
Central administration of oxytocin in rodents is anorexigenic,
and rodents that lack oxytocin or the oxytocin receptor become1, March 26, 2015 ª2015 Elsevier Inc. 123
obese (Olson et al., 1991). The exact sites of action of locally
released oxytocin are unknown but likely involve areas with
high oxytocin receptor expression, such as the VMH and amyg-
dala. a-MSH, through its effects on MC4R, induces dendritic
release of oxytocin, and this locally released oxytocin may be
involved in the regulation of appetite (Sabatier et al., 2003). Mod-
ulation of central oxytocin signaling therefore forms another
potential target in the treatment of obesity (Morton et al., 2014).
Neural Circuits Involved in Eating Behavior
The most consistent phenotype associated with genetic disrup-
tion of leptin-melanocortin signaling in humans is hyperphagia,
an increased drive to eat (O’Rahilly and Farooqi, 2008). Addition-
ally, detailed characterization of eating behavior in large
numbers of twins suggests that eating behavior phenotypes
such as satiety responsiveness, eating in the absence of hunger,
reinforcing value of food, and the capacity to voluntarily inhibit
eating are potentially heritable components of eating behavior
(Carnell et al., 2008).This is not surprising, as one of the primary
functions of the brain during periods of negative energy balance
is to reprioritize behavioral outputs to obtain and consume food,
thereby replenishing depleted energy stores. Ensuring sufficient
energy stores is critical for survival of the species and, based on
our understanding in other mammalian species, multiple pro-
cesses that defend against starvation and fasting are hardwired.
In addition to this homeostatic regulation of eating behavior,
which is driven by energy demands, hedonic food intake (i.e.,
beyond the need for energy repletion) in response to the
rewarding properties of food (Kenny, 2011) is an important
contributor to overeating. The palatability of a particular food
source is assumed to be related to the flavor and taste of that
food; high-fat diets are generally considered more palatable
than low-fat diets and are preferentially overconsumed. Neural
circuits involving the amygdala, the striatonigral pathway, orbito-
and prefrontal cortex, and hippocampus have been implicated
in transposing motivational aspects of stimuli into motor re-
sponses, as well as in hedonic evaluation of the stimulus and
associative learning about the hedonic properties of food
(Figure 3). Food reward has been considered to be encoded by
distinct neural substrates, opioidergic brain pathways mediating
liking (pleasure/palatability), whereas the wanting of food (incen-
tive motivation) appears to be mediated by dopaminergic cir-
cuits (Berridge, 1996; Pecina et al., 2003). The overarching role
of these responses is to shift attention and effort toward obtain-
ing food reward.
Hormonal regulators of energy homeostasis can also act on
brain reward circuits, most notably on the mesoaccumbens
dopamine system, to increase or decrease the incentive value
of food depending on energy requirements. This suggests that
obtaining the pleasurable effects of food is a powerful moti-
vating force that can override homeostatic satiety signals, and
in agreement with this, meals that consist of palatable food
are generally consumed with greater frequency and in greater
portion size than those consisting of less palatable food. As a
single meal of increased portion size can trigger increased
food intake over several days, such hedonic overeating is likely
to be an important contributor to weight gain and the develop-
ment of obesity.124 Cell 161, March 26, 2015 ª2015 Elsevier Inc.Human Brain Imaging Studies—Insights into Food
Reward
Neural processes such as food reward can be challenging to
measure in humans. Imaging studies using functional MRI
(fMRI) permit the measurement of blood-oxygen-level depen-
dent (BOLD) signals that reflect neural activity in specific regions
involved in the response to food cues (Selvarajah et al., 2014).
Pictures of food activate dopaminergic regions such as ventral
striatum, and these effects are modulated by homeostatic state
(Ziauddeen et al., 2012). In leptin-deficient humans, images of
food (compared to non-food images) are associated with a
marked increase in neuronal activation in the ventral striatum
(Farooqi et al., 2007a). This response was normalized by
7 days of leptin treatment before significant weight loss had
occurred, consistent with the view that activation in the ventral
striatum does not directly encode the ‘‘liking’’ but, rather, the
motivational salience, or ‘‘wanting,’’ of food. Studies in obese
volunteers in an energy-restricted, partially leptin-deficient state
are consistent with the view that these responses are part of the
physiological response to energy restriction (Rosenbaum et al.,
2008) and are in keeping with findings in experimental studies
in rodents (Fulton et al., 2006; Hommel et al., 2006).
Compared to obese controls, obese people withMC4Rmuta-
tions have a preserved pattern of activation of the reward system
to visual food cues, suggesting involvement of MC4R in the
dopaminergic reward circuitry in humans (van der Klaauw
et al., 2014). These findings are supported by evidence in ro-
dents, which suggests that melanocortin signaling modulates
food reward. Of note, fMRI studies in Prader-Willi Syndrome
have also shown higher neural activity to food cues in reward
areas compared to matched obese controls such as accum-
bens, amygdala, and ventromedial prefrontal cortex (Hinton
et al., 2006).
The m-opioid receptor system that subserves the neural sub-
strates of ‘‘liking of food’’ is a key mediator in the hedonic valu-
ation process of food intake. In addition, m-opioid receptors
were found to mediate the autoinhibition of b-endorphin on hy-
pothalamic pomc neurons (Cowley et al., 2003). Antagonism of
m-opioid receptors thus likely results in alterations of hedonic
valuation of food as well as potentially attenuates downregula-
tion of pomc neuronal activity. Indeed, in humans, the m-opioid
receptor antagonist naloxone reduces the hedonic responses
to, and consumption of, palatable foods. In clinical trials, the
m-opioid receptor antagonist GSK1521498 reduces the hedonic
response to and motivation for high-fat foods (Ziauddeen et al.,
2013). Recently, the combination of naltrexone, an opioid recep-
tor antagonist with high affinity for the m-opioid receptor, and
bupropion, an atypical antidepressant that inhibits reuptake of
dopamine and norepinephrine and increases activity of POMC
neurons (Contrave) was approved for treatment of obesity by
the FDA.
Taste and Food Preference
The orosensory properties of foods are perceived through a
combination of taste, texture, and olfaction. The heritability of
taste is well established in twin and family studies, with heritabil-
ity estimates of 30%–50% for pleasantness, consumption, and
cravings for sweet foods (Keskitalo et al., 2008). The central
sensing mechanisms for nutrients and quality of food have only
recently become the subject of studies. Fat provides twice as
many calories per gram as protein or carbohydrate. It is well
established that palatable food that is rich in fat and refined
sugars promotes larger meal sizes, less postprandial satiety,
and greater caloric intake than diets that are high in carbohy-
drates but low in fat (Salbe et al., 2004). Traditionally, there
have been contrasting perspectives on the mechanisms under-
lying food palatability. The homeostatic view of palatability sug-
gests that palatability reflects the underlying biological need for
nutrients, while the hedonic view of palatability suggests that
certain foods engage reward processing and are therefore palat-
able. Studies in rodents have suggested that specific neural
pathways, for example, involving the melanocortin-4 receptor
(Mc4r), play a role in the preference for dietary fat and against di-
etary sucrose (Panaro andCone, 2013). To date, very few studies
have addressed the preference for specific nutrients in humans,
although twin studies have found heritability estimates of 53%–
62% for the intake of/preference for foods that are high fat/
sucrose. There is considerable research being performed within
the food industry focusing on the development of foods that offer
some of the sensory properties of fat (fat mimetics) but do not
have a high fat content. The potential to modify foods for health
benefits is an area of considerable development; such work will
need to take into consideration an understanding of the funda-
mental biology that underpins aspects of eating behavior.
Gut-Derived Satiety Signals
Peptides such as ghrelin, peptide YY (PYY), and glucagon-like
peptide 1 (GLP-1) are secreted from gut entero-endocrine cells
in response to meal ingestion and the presence of nutrients in
the intestinal lumen (Batterham et al., 2002; Turton et al.,
1996). Pioneering human infusion studies have demonstrated
that a number of gut peptidesmodulate food intake when admin-
istered acutely in humans (Tan and Bloom, 2013), suggesting
that modulating satiety signals could be a useful therapeutic
strategy in obesity (Finan et al., 2015). The synthetic GLP-I re-
ceptor agonist liraglutide has recently been approved for the
treatment of obesity alone by the FDA. Several other gut peptide
analogs, as well as gut hormone receptor agonists, are currently
being studied in clinical trials (Tan and Bloom, 2013).
Satiation, the sensation of fullness that results in meal termina-
tion and satiety, the persistence of fullness that determines the
timing to the next meal, are heritable traits that influence weight
gain (Carnell et al., 2008). Although common obesity seems to
be associated with low circulating PYY levels (Batterham et al.,
2006), rare genetic variants in PYY or its receptors have not
been associated with obesity. Fasting ghrelin levels have been
found to be increased in children (Haqq et al., 2003) and adults
with PWS (Cummings et al., 2002), potentially contributing to the
hyperphagia and impaired satiety associated with this syndrome,
although the potential mechanisms involved are not known.
Additionally, there is a growing literature on changes in the
composition of the gut microbiome in response to acute/short-
term changes in the diet, chronic states such as obesity and bar-
iatric surgery (Turnbaugh et al., 2006), and the impact of specific
organisms on nutrient absorption and on metabolic parameters
in mice and humans (Cox et al., 2014).Targeting Energy Expenditure
A number of large family-based population studies, most notably
the Quebec family study, have addressed the contribution
of genetic versus environmental factors to energy expenditure,
including physical activity (Pe´russe et al., 1989). For example,
the heritability of exercise participation is entirely accounted
for by common familial environment, while for physical activity
level, the heritability is 20%. As such, promotion of increased
levels of physical activity is a useful strategy for weight loss
and, in particular, for weight maintenance.
In contrast, basal metabolic rate (BMR) and respiratory
quotient (ratio of carbohydrate versus fat oxidation; a marker of
substrate utilization) are highly heritable (47% and 36%, respec-
tively) (Bouchard and Tremblay, 1990). Very few genes have
been shown to modulate BMR in humans, although the reduced
basal metabolic rate reported in obese people harboring loss-
of-function mutations in the cellular scaffolding protein KSR2
(kinase suppressor of Ras2) suggests that genetic variation in
energy expenditure phenotypes may contribute to weight gain
in some individuals (Pearce et al., 2013). In this study, almost
all of the KSR2 variants identified in obese individuals impaired
glucose oxidation and fatty acid oxidation in cells, suggesting
a defect in substrate utilization, which was rescued by the addi-
tion of metformin. Further work will be needed to see whether
these observations can be replicated in experimental clinical
studies and to investigate the cellular mechanisms underlying
these effects which, in part, may be mediated by the interaction
of KSR2 with the cellular fuel sensor, AMP-kinase (Brommage
et al., 2008; Costanzo-Garvey et al., 2009).
The development of compounds that might increase energy
expenditure is being explored as a possible therapeutic strategy.
One potential route is to activate brown adipose tissue, thereby
generating heat through uncoupling protein 1 (UCP1) (Lowell and
Spiegelman, 2000). UCP1-positive cells in white adipose tissue
depots in rodents (often called beige/brite cells) can be stimu-
lated to dissipate energy by thermogenesis and pharmacological
stimulation of these processes, potentially through circulating
myokines that drive brown-fat-like development (Wu et al.,
1999), has attracted the interest of a number of pharmaceutical
companies. Although UCP1-positive cells that show similarity
tomurine beige adipocytes have been found in human fat depots
(Wu et al., 1999), the translation of these findings in rodents to
therapies that can be administered safely in humans presents
some challenges. For example, what influences the exact
amount of brown fat and/or beige fat available in adult humans,
and can this be increased? To what extent do sex steroids (or
other gender-specific factors) influence the activity/quantity of
brown/beige fat, as women seem to have more than men (Cyp-
ess et al., 2009)? How much extra energy would be expended
through the stimulation/overstimulation of such processes, and
would this be clinically relevant? Would an increase in energy
expenditure lead to a compensatory increase in food intake,
and how might such an effect be managed?
Building an Integrated View of the Pathways that
Regulate Energy Homeostasis
Given the complexity of neurobiological processes underlying
body weight homeostasis, it is likely that future drugs will needCell 161, March 26, 2015 ª2015 Elsevier Inc. 125
Figure 4. Types of Genetic Variation Contributing to Body Weight Regulation
Genetic effects on body weight are mediated by different types of variants, their frequency in the population, and the effect of the variant on the phenotype.
Variants include single-nucleotide variations in which only one nucleotide is changed, copy number variations in which a stretch of DNA is repeated or deleted
(often containing many genes), or small insertions and deletions of a few base pairs. Common variants are found at a minor allele frequency (MAF) of more than
5% in a population, whereas intermediate (1%–5%) and rare variants (< 1%) are found at lower frequencies. Generally, the effect size of common obesity-
associated variants on body weight is modest. Several rare variants have been associated with severe obesity.to be directed at highly specific targets and may consist of com-
binations of compounds that target different mechanisms, as
illustrated by recent studies demonstrating the efficacy of dual
melanocortin-4 receptor and GLP-1 receptor agonism (Clem-
mensen et al., 2015). The central and peripheral regulation of
food intake, energy expenditure, physical activity, fat absorption,
and oxidation are all being explored as potential mechanisms
that can be targeted in rodent studies. In parallel, genetic ap-
proaches into human eating behavior and obesity may inform
the focus of experimental approaches in rodents and might
generate new potential drug targets in which the potential
relevance to humans may be established at an earlier stage
than has previously been the case.
Common Genetic Variants and Genome-wide
Association Studies
Genetic influences are likely to operate across the weight spec-
trum but may bemore penetrant when studying childhood-onset
obesity and at both extremes of the BMI distribution—thinness
and severe obesity. Genetic variance depends on the nature
and amount of mutational variance in a population, the segrega-
tion and frequency of the alleles that influence a trait in a partic-
ular population, the effect sizes of the variants (which may be
additive or non-additive), the mode of gene action, and the
degree of genetic control of phenotypic variance of the trait in
question (Figure 4).
Genome-wide association studies (GWAS) seek to identify the
common variants (minor allele frequency [MAF] of more than 5%)
that contribute to the heritability of common diseases. High-
throughput arrays have facilitated the genotyping of thousands
of common variants (directly or by imputation) in large popula-
tion-based cohorts on whom BMI data is available. The first
GWAS-derived loci to be reported were intronic variants in
FTO (fat mass and obesity associated) and a variant 200 kb
downstream of MC4R (Dina et al., 2007; Frayling et al., 2007;
Loos et al., 2008). To date, more than 80 genetic loci associated
with BMI and body fat distribution (often measured by waist-to-
hip ratio) have been identified by GWAS approaches, and many
of these have been replicated in different populations and ethnic-
ities (Locke et al., 2015). GWAS in childhood-onset obesity and126 Cell 161, March 26, 2015 ª2015 Elsevier Inc.in severely obese children and adults have shown that there is
some overlap between the common variants that contribute to
early-onset and adult-onset weight gain, but also that both of
these approaches can identify novel variants (Bradfield et al.,
2012; Wheeler et al., 2013). Cumulatively, the common variants
identified in GWAS are characterized by modest effect sizes
(per allele odds ratios between 1.1 and 1.5), and the proportion
of variability of BMI explained by GWAS-identified loci to date
remains relatively modest (< 5%). Nevertheless, variants that
explain a small proportion of phenotypic variance may provide
substantial biological or therapeutic insights, although the road
to establishing causal variants and their functional relevance is
often a challenging one.
GWAS-associated loci are often identified by the name of the
nearest gene; this may or may not be the gene in which variation
contributes to variation in BMI. Some of the GWAS loci encom-
pass genes previously appreciated to play a role in energy
homeostasis (e.g., LEPR, SH2B1, MC4R, BDNF), and in some
cases, specific variants have been associated with changes in
expression based on eQTL data (Wheeler et al., 2013). Other
loci contain genes that seem to be plausible biological candi-
dates or can suggest genes for which there was no previous
evidence (Locke et al., 2015). Many of the signals identified to
date map to non-coding regions of the genome that may poten-
tially be involved in gene regulation.
The strongest association signal for BMI has consistently
been found with variants in the first intron of FTO, which have
been associated with increased BMI and eating behavior in a
number of studies (Cecil et al., 2008; Wardle et al., 2008a).
Deletion or overexpression of fto and other genes in this region
(IRX3, RPGRIP1L) in rodents (Church et al., 2010; Fischer
et al., 2009; Gerken et al., 2007; Stratigopoulos et al., 2008)
(Smemo et al., 2014) can impact energy homeostasis. Despite
these obvious challenges, these studies have demonstrated
progress toward identifying new biology based on GWAS
(Tung et al., 2014).
Is there yet more common variation to find? Newly developed
statistical methods that assess the contribution of common
genetic variation across the genome (Zhu et al., 2015) support
the growing consensus that there is a long tail of common
variation. As such, meta-analyses of even larger population-
based data sets are currently underway. The available evidence
suggests that BMI is highly polygenic (high number of contrib-
uting genes) (Gusev et al., 2014). One of the challenges of
such studies is how to capture the full spectrum of genetic vari-
ation (Figure 4), including complex multi-allelic CNVs, which
show lower linkage disequilibrium with surrounding SNPs and
are consequently less detectable by conventional SNP-based
genome-wide association studies. For example, in a large fam-
ily-based association study of Swedish families ascertained
through the identification of siblings who were discordant for
obesity, integrating data from CNV analysis with transcriptomic
data from adipose tissue revealed an association with copies of
AMY1 with obesity (Falchi et al., 2014).
Finding New Rare Highly Penetrant Variants
Rare variants, which outnumber common variants in the human
genome, may explain a proportion of the heritability of obesity
and may be more readily identified at the extremes of the
phenotypic distribution. The earliest studies were performed in
children with clinically identifiable syndromes often associated
with developmental delay or dysmorphic features as well as
obesity. Rare CNVs that often disrupt a number of genes have
recently been implicated in highly penetrant forms of obesity
(Bochukova et al., 2010; Walters et al., 2010). Candidate gene
studies based on the molecules known to cause severe obesity
in experimental animals have shown that these genes also
contribute to childhood-onset human obesity, often in the
absence of developmental delay. The functional and physiolog-
ical characterization of these mutations and of the mutation
carriers has illustrated a high degree of convergence of the
mechanisms that regulate energy balance across mammalian
species.
Exome sequencing of cohorts with severe childhood-onset
and adult-onset obesity, as well as those at the extremes of
the BMI distribution in population-based cohorts, is well under-
way and may lead to the identification of new genes whose
functions will need to be explored in cells, model organisms,
and humans. Whole-genome sequencing provides the ‘‘most
complete’’ view of genomic variation but poses challenges in
terms of proving causality, but these are beginning to be ad-
dressed. Recent studies have now shown that human inducible
pluripotent stem cell (iPSC)-derived neurons may facilitate a
mechanistic understanding of how specific genes disrupt
cellular and neuronal mechanisms that may be involved in the
pathogenesis of obesity (Wang et al., 2015).
Therapeutics Opportunities in Obesity
Lifestyle modification remains the first step in weight manage-
ment.While intervention programs that focus on supporting peo-
ple to change their diet and/or levels of physical activity can be
effective in inducing weight loss in the short to medium term in
some people, they lose efficacy in the long term. As such, in
addition to the focus on prevention of obesity, treatment of
obese patients, preferably at a stage before complications
have emerged, is an important priority (Gray et al., 2012). How-
ever, current therapeutic options in obesity are very limited; the
only currently approved anti-obesity drug for long-term use inthe US and Europe is Orlistat, which reduces intestinal lipid ab-
sorption by inhibiting pancreatic lipase and often has limiting
adverse effects that preclude its long term use.
Previously available anti-obesity drugs targeted cannabinoid
signaling (rimonabant), noradrenergic (phentermine) and seroto-
ninergic signaling (fenfluramine, dexfenfluramine), and reuptake
(sibutramine). These compounds were moderately effective
but, as with many centrally acting agents, at the expense of
many off-target effects, reflecting lack of specificity of the neural
targets. Lorcaserin, a selective 5HT2cR agonist with limited ac-
tivity at the other serotonin receptors, has been approved for
use in the US (Smith et al., 2010), although concerns about
potential cardiac valvulopathy and cancer risk have prevented
European approval of the drug to date. The combination of the
anticonvulsant topiramate and phentermine, which increases
central noradrenaline levels (Qsymia), is also approved in some
countries.
Finally, development of personalized medicine by selecting
the optimal pharmacological intervention for particular people
through genetics or other molecular/cellular analyses is an
exciting and evolving area. Synthetic-biology-inspired therapeu-
tic systems that integrate sensor and effector devices into cells
have been developed to monitor disease-relevant metabolites,
process on/off level control, and coordinate adjusted therapeutic
responses. These systems have the potential to restore metab-
olite homeostasis in a seamless, automatic, and self-sufficient
manner, which is particularly attractive for future gene- and
cell-based therapies. As an example, a closed-loop synthetic
intracellular lipid-sensing receptor (LSR)-pramlintide circuit rep-
resents a potential prototype for such a cell-based therapy. The
LSR sensor captures a wide range of lipids within their physio-
logic concentration range, becomes dose-dependently acti-
vated by peak fatty acid levels, and is turned off at physiological
concentrations (Ro¨ssger et al., 2013). Such emerging methodol-
ogies offer fresh perspectives for drug delivery and potentially
personalized medicine in the future.
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